Double Flops For Merck's Lung Cancer Studies
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) reported that its Phase 2 KeyVibe-002 trial for a lung cancer treatment combo did not meet statistical significance. The trial involved vibostolimab/pembrolizumab with or without docetaxel for metastatic NSCLC. Additionally, Merck will discontinue the Phase 3 KEYLYNK-008 trial of Keytruda with Lynparza due to lack of improvement in overall survival. MRK shares dropped 0.76% following the news.
December 07, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Merck's lung cancer treatment trials failed to meet statistical significance, leading to the discontinuation of a Phase 3 trial. This negative outcome may impact investor confidence and the stock price.
Clinical trial results are critical for pharmaceutical companies like Merck. The failure to meet statistical significance in these trials is a setback for the company's oncology pipeline and could lead to negative sentiment among investors, potentially causing a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100